Clover Health Investments (CLOV) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Clover Health Investments (CLOV) has outperformed Veracyte (VCYT) over the past year, gaining 63.6% versus a loss of 42.9%. Over five years, CLOV leads with a -31.1% price change compared with -39.5% for VCYT. Veracyte is the larger company by market cap ($2.03 billion vs $2.00 billion), about 1.0 times the size, while Clover Health Investments is growing revenue faster (+40.3% vs +16.0%).
On valuation, Veracyte trades at a lower forward P/E (16.2x vs 20.7x for Clover Health Investments). Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -4.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLOV | VCYT |
|---|---|---|
| Share price | $3.73 | $25.13 |
| Market cap | $2.00B | $2.03B |
| 1-day change | -1.06% | +0.36% |
| YTD return | +58.72% | -40.31% |
| 1-year return | +63.60% | -42.90% |
| 5-year return | -31.05% | -39.53% |
| P/E ratio (TTM) | 373.00 | 16.32 |
| Forward P/E | 20.72 | 16.15 |
| EPS (TTM) | $0.01 | $1.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.92B | $517.14M |
| Revenue growth (YoY) | +40.34% | +16.01% |
| Net income (latest FY) | $-85.55M | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | -4.44% | 11.17% |
| Net margin | -4.45% | 12.83% |
| 52-week high | $5.59 | $60.91 |
| 52-week low | $1.58 | $21.91 |
| Distance from 52-week high | -33.27% | -58.74% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +50.13% | +77.48% |
| Average volume | 4.49M | 1.89M |
| Shares outstanding | 439.71M | 80.70M |
| Employees | 724 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLOV has outperformed VCYT by 106.5 percentage points over the past year.
- Clover Health Investments trades at a higher earnings multiple (373.0x vs 16.3x trailing P/E).
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -4.4 cents for Clover Health Investments.
- Clover Health Investments grew revenue faster in its latest fiscal year (+40.34% vs +16.01%).
About Clover Health Investments
CLOV stock →Clover Health Investments, Corp. provides medicare advantage plans in the United States.
Health Care · Medical Specialities · 724 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
CLOV vs VCYT FAQ
Which is bigger, Clover Health Investments or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $2.03B compared with $2.00B for Clover Health Investments (CLOV).
Which stock has performed better over the past year, CLOV or VCYT?
CLOV returned +63.60% over the past 12 months, compared with -42.90% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CLOV or VCYT?
VCYT has the lower trailing P/E at 16.3, versus 373.0 for CLOV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Clover Health Investments and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.